The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies

SUMMARY: This post hoc analysis of the UNITI studies found ustekinumab (UST) did not significantly improve overall extraintestinal manifestations (EIMs) of Crohn's disease compared to placebo‐treated patients at weeks 6 and 52. BACKGROUND AND AIMS: The UNITI trials demonstrated that UST was eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Narula, Neeraj, Aruljothy, Achuthan, Wong, Emily C. L., Homenauth, Ravi, Alshahrani, Abdul‐Aziz, Marshall, John K., Reinisch, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259251/
https://www.ncbi.nlm.nih.gov/pubmed/34077627
http://dx.doi.org/10.1002/ueg2.12094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259251/
https://www.ncbi.nlm.nih.gov/pubmed/34077627
http://dx.doi.org/10.1002/ueg2.12094

Ejemplares similares